Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.

Open access

Abstract

In the approval process for new weight management therapies, regulators typically require estimates of effect size. Usually, as with other drug evaluations, the placebo-adjusted treatment effect (i.e., the difference between weight losses with pharmacotherapy and placebo, when given as an adjunct to lifestyle intervention) is provided from data in randomized clinical trials (RCTs). At first glance, this may seem appropriate and straightforward. However, weight loss is not a simple direct drug effect, but is also mediated by other factors such as changes in diet and physical activity. Interpreting observed differences between treatment arms in weight management RCTs can be challenging; intercurrent events that occur after treatment initiation may affect the interpretation of results at the end of treatment. Utilizing estimands helps to address these uncertainties and improve transparency in clinical trial reporting by better matching the treatment-effect estimates to the scientific and/or clinical questions of interest. Estimands aim to provide an indication of trial outcomes that might be expected in the same patients under different conditions. This article reviews how intercurrent events during weight management trials can influence placebo-adjusted treatment effects, depending on how they are accounted for and how missing data are handled. The most appropriate method for statistical analysis is also discussed, including assessment of the last observation carried forward approach, and more recent methods, such as multiple imputation and mixed models for repeated measures. The use of each of these approaches, and that of estimands, is discussed in the context of the SCALE phase 3a and 3b RCTs evaluating the effect of liraglutide 3.0 mg for the treatment of obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41366-020-00733-x

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Intercurrent events and their implications in weight management clinical trials. CI confidence interval, ETD estimated treatment difference. aIntercurrent events are likely to be unbalanced between treatment arms, potentially introducing bias. bAdopting other weight-loss medication recorded as concomitant medication during the trial. Non-pharmacological measures could also be considered, e.g., actively engaging in additional weight-loss programs such as joining a gym or commercial weight-loss program, or bariatric surgery.
Fig. 1 Intercurrent events and their implications in weight management clinical trials. CI confidence interval, ETD estimated treatment difference. aIntercurrent events are likely to be unbalanced between treatment arms, potentially introducing bias. bAdopting other weight-loss medication recorded as concomitant medication during the trial. Non-pharmacological measures could also be considered, e.g., actively engaging in additional weight-loss programs such as joining a gym or commercial weight-loss program, or bariatric surgery.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. National Research Council. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Washington DC, USA: Committee on National Statistics, Division of Behavioral and Social Sciences and Education, The National Academies Press; 2010.

Cited by

See all 59

Metadata

Authors
Wharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., Wadden, T. A., & Wilding, J. P. H.
Affiliations
  • York University (CA)
  • University of Copenhagen (DK)
  • Novo Nordisk (Denmark) (DK)
  • Glasgow Royal Infirmary (GB)
  • University of Pennsylvania (US)
  • University of Liverpool (GB)
Corresponding author
Wharton, Sean
Venue
International Journal of Obesity
Published
2021-01-18
Volume
45
Issue
5
Pages
923-933
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W3121599370
Cited by
58
References
21
Citations by year
2026: 9 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 12 · 2021: 6
FWCI
1.85
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Obesity (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Funders
Novo Nordisk
Topics
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods and Bayesian Inference
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
estimands, intercurrent events, missing data, weight management, obesity pharmacotherapy, liraglutide, last observation carried forward, multiple imputation, clinical trial reporting, weight loss
MeSH terms
Body Weight, Data Interpretation, Statistical, Humans, Obesity, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. https://app.cochat.ai/papers/10.1038/s41366-020-00733-x
The paper
Wharton, S., Astrup, A., Endahl, L., Lean, M. E. J., Satylganova, A., Skovgaard, D., Wadden, T. A., & Wilding, J. P. H. (2021). Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. International Journal of Obesity. https://doi.org/10.1038/s41366-020-00733-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.